Breast cancers in the 485 patients were classified into molecular subtypes as follows: 93 (19.2%) Luminal A; 242 (49.9%) Luminal B; 108 (22.3%) HER2; and 42 (8.7%) Basal. Here, ERBB2 is linked to breast carcinoma.